Table 2 Patient characteristics during combined imatinib/IFN-α therapy
Patient | Disease status at IFN-α start | Interval imatinib start to IFN-α addition (months) | DFS (mo.) since imatinib start | Site of relapse | Relapse therapy | Duration of combination (months) | OS (mo.) since imatinib start | Outcome |
|---|---|---|---|---|---|---|---|---|
1 | MRD+ | 3.4 | 21.4+ | — | — | 18+ | 21.4+ | Ongoing CHR, MRD decline |
2 | MRD+ | 4.8 | 20.81+ | — | — | 16+ | 20.8+ | Ongoing CHR, MRD− |
3 | MRD+ | 3.5 | 9 | Isolated CNS relapse | i.t. therapy, CNS-irr., imatinib+IFN-α | 17+* | 20.5+ | Ongoing CHR, MRD− |
4 | MRD+ | 3.8 | 6.4 | Isolated CNS relapse | i.t. therapy, CNS-irr., imatinib+IFN-α | 15.3+** | 19.1+ | Ongoing CMR, MRD− |
5 | MRD+ | 4 | 5 | BM relapse | 6-MP, MTX, imatinib | 1 | 10.5 | Dead |
6 | Refractory first relapse, imatinib failure | 0.5 | 5.4 | BM relapse | Second auto-SCT, MUD-SCT | 5 | 14.3 | Dead |
Median (range) | 3.7 (0.5–4.8) | 8 (5–21.4+) | 15.7 (1–18+) | 20 (10.5–21.4+) |
